Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Dosing has begun in a randomized study of CPI-1205 / enzalutamide combination versus enzalutamide alone in second-line mCRPC Single-arm CPI-1205 […]